Skip to main content

Citizens JMP Reaffirms Their Buy Rating on ProQR (PRQR)

Tipranks - Tipranks - Sat Jun 28, 2025

In a report released today, Jonathan Wolleben from Citizens JMP reiterated a Buy rating on ProQR (PRQR – Research Report), with a price target of $8.00. The company’s shares closed yesterday at $2.16.

Confident Investing Starts Here:

According to TipRanks, Wolleben is a 4-star analyst with an average return of 7.1% and a 45.09% success rate. Wolleben covers the Healthcare sector, focusing on stocks such as Rhythm Pharmaceuticals, Altimmune, and Madrigal Pharmaceuticals.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for ProQR with a $9.33 average price target.

See today’s best-performing stocks on TipRanks >>

Based on ProQR’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $4.52 million and a GAAP net loss of $10.08 million. In comparison, last year the company earned a revenue of $4.48 million and had a GAAP net loss of $7.7 million

Read More on PRQR:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).